Table 1.
Baseline characteristics of study patients
| Parameter | RFA + Sorafenib group | Sorafenib group | χ2/t | P-Value |
|---|---|---|---|---|
| Age (years) | 55.7 ± 11.2 | 56.1 ± 9.6 | 0.290 | 0.771 |
| Sex | 0.183 | 0.668 | ||
| Male | 88 | 107 | ||
| Female | 14 | 20 | ||
| Hepatitis virus | 0.107 | 0.947 | ||
| HBV | 89 | 109 | ||
| HCV | 6 | 8 | ||
| Negative | 7 | 10 | ||
| Platelet count (× 109/L) | 131.4 ± 28.5 | 127.1 ± 32.2 | 1.056 | 0.291 |
| Serum AST (IU/L) | 41.7 ± 10.3 | 42.3 ± 11. 2 | 0.417 | 0.676 |
| Serum ALT (IU/L) | 36.4 ± 8.1 | 35.1 ± 10.7 | 1.015 | 0.311 |
| Total bilirubin (μmol/L) | 12.5 ± 11.7 | 11.8 ± 12.3 | 0.437 | 0.662 |
| Maximum diameter of primary tumor (cm) | 8.8 ± 2.7 | 8.3 ± 3.0 | 1.310 | 0.191 |
| 0.002 | 0.958 | |||
| 5~10 cm | 71 | 88 | ||
| ≥ 10 cm | 31 | 39 | ||
| AFP level (ng/L) | 0.002 | 0.957 | ||
| ≥ 400 | 63 | 78 | ||
| < 400 | 39 | 49 | ||
| No. of tumors | 0.906 | 0.635 | ||
| ≥ 3 | 32 | 33 | ||
| 2 | 20 | 29 | ||
| 1 | 50 | 65 | ||
| Child-Pugh class | 0.493 | 0.482 | ||
| A | 90 | 108 | ||
| B | 12 | 19 | ||
| Local remnants after TACE | 0.627 | 0.428 | ||
| < 50% | 74 | 86 | ||
| ≥ 50% | 28 | 41 | ||
| ECOG performance | 0.344 | 0.557 | ||
| 0 | 85 | 102 | ||
| 1 | 17 | 25 |
Note: AFP = a-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus.